Hemenway Trust Co LLC lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 71.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,750 shares of the medical instruments supplier's stock after selling 36,455 shares during the quarter. Hemenway Trust Co LLC's holdings in Becton, Dickinson and Company were worth $3,379,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in BDX. Hillsdale Investment Management Inc. grew its holdings in shares of Becton, Dickinson and Company by 1.7% during the fourth quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier's stock worth $694,000 after purchasing an additional 50 shares in the last quarter. Americana Partners LLC grew its stake in Becton, Dickinson and Company by 3.5% in the 4th quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier's stock worth $345,000 after buying an additional 52 shares in the last quarter. Alpha Omega Wealth Management LLC grew its stake in Becton, Dickinson and Company by 5.7% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after buying an additional 53 shares in the last quarter. Picton Mahoney Asset Management increased its holdings in shares of Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after buying an additional 54 shares during the last quarter. Finally, REAP Financial Group LLC raised its position in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after buying an additional 55 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Becton, Dickinson and Company Price Performance
Shares of Becton, Dickinson and Company stock opened at $170.01 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The business's 50 day simple moving average is $181.67 and its two-hundred day simple moving average is $212.31. The stock has a market capitalization of $48.73 billion, a P/E ratio of 32.45, a price-to-earnings-growth ratio of 1.30 and a beta of 0.25.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping the consensus estimate of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm earned $3.17 earnings per share. Analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, June 9th. This represents a $4.16 annualized dividend and a dividend yield of 2.45%. Becton, Dickinson and Company's payout ratio is presently 79.39%.
Analysts Set New Price Targets
Several brokerages recently issued reports on BDX. Wall Street Zen lowered shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. William Blair cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Piper Sandler cut Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $260.00 to $185.00 in a report on Friday, May 2nd. Barclays cut their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Finally, Raymond James Financial downgraded shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of "Hold" and a consensus price target of $219.22.
Check Out Our Latest Analysis on Becton, Dickinson and Company
Insider Activity at Becton, Dickinson and Company
In related news, EVP Michael David Garrison sold 479 shares of the firm's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the sale, the executive vice president now owns 4,887 shares of the company's stock, valued at $964,107.36. This trade represents a 8.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president now directly owns 4,575 shares of the company's stock, valued at approximately $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is owned by company insiders.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
